Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
D Belada, K Kopeckova, JM Bergua Burgues… - Blood, 2023 - ashpublications.org
Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients
with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for …
with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for …
Aggressive B cell lymphomas—highlights from ASH 2022
M Panny - memo-Magazine of European Medical Oncology, 2023 - Springer
The treatment landscape of aggressive B cell lymphomas has changed substantially in
recent years. Several therapeutic agents changed the dogma of diffuse large B cell …
recent years. Several therapeutic agents changed the dogma of diffuse large B cell …
[PDF][PDF] What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment …
G Brisou, P Staber - emjreviews.com
What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in
Second-Line Diffuse Large B Cell Lympho Page 1 2 What to Do When Chimeric Antigen …
Second-Line Diffuse Large B Cell Lympho Page 1 2 What to Do When Chimeric Antigen …
[HTML][HTML] Phillips Discusses Treatment Options for Early-Relapsed DLBCL
TO Staff - 2023 - targetedonc.com
Phillips Discusses Treatment Options for Early-Relapsed DLBCL NEWS All NewsFDA BriefsOncology
IconsSpecial ReportsVoices from the Field CONFERENCES Conference CoverageConference …
IconsSpecial ReportsVoices from the Field CONFERENCES Conference CoverageConference …
[HTML][HTML] Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL
TO Staff - 2023 - targetedonc.com
Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL NEWS All NewsFDA
BriefsOncology IconsSpecial ReportsVoices from the Field CONFERENCES Conference …
BriefsOncology IconsSpecial ReportsVoices from the Field CONFERENCES Conference …
[HTML][HTML] Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
TO Staff - 2023 - targetedonc.com
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL NEWS
All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field CONFERENCES …
All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field CONFERENCES …